# OnCo record financial-toxicity (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/financial-toxicity/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "financial-toxicity" ;
  schema:name "Financial toxicity"@en ;
  schema:description "The harm caused to patients by the cost of cancer care: depleted savings, debt, skipped medication and worse survival. Measured like any other side effect and, increasingly, treated like one."@en ;
  schema:url <https://onco.cc/terms/financial-toxicity/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Financial_toxicity> ;
  schema:citation <https://doi.org/10.1634/theoncologist.2012-0279>, <https://www.facit.org/measures/facit-cost>, <https://www.macmillan.org.uk/cancer-information-and-support/impacts-of-cancer/work-and-cancer>, <https://www.macmillan.org.uk/cancer-information-and-support/get-help/financial-and-work>, <https://www.pancreaticcancer.org.uk/information-and-support/dealing-with-pancreatic-cancer/daily-life-with-pancreatic-cancer/work-and-money/>, <https://www.bowelcanceruk.org.uk/about-bowel-cancer/living-with-and-beyond-bowel-cancer/work,-money-and-travel/>, <https://www.colostomyuk.org/information/returning-to-work-after-stoma-surgery/>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.gov.uk/statutory-sick-pay> ;
  onco:tag "gap-fill" ;
  onco:related <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/terms/drug-price-transparency/>, <https://onco.cc/terms/cancer-health-disparities/>, <https://onco.cc/technologies/rejuv-life-money-after-treatment/>, <https://onco.cc/technologies/rejuv-life-return-to-work/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/splenic-marginal-zone-lymphoma/>, <https://onco.cc/cancers/nodal-marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/angioimmunoblastic-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/sezary-syndrome/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zafar-oncologist/> .